Industry & Pharma feed

ZURZUVAE® Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan

OSAKA, Japan, March 19, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Offi...

US FDA’s New Approach Methodologies Framework Rests On Four Validation Pillars

JenaValve’s Trilogy Becomes First FDA-Approved TAVR Treatment For Aortic Regurgitation

The FDA approved JenaValve’s Trilogy HeartValve for treating severe aortic regurgitation, marking it...

Mar 18, 2026 4:30 PM EDTXOMA Royalty Declares Quarterly Preferred Stock Dividends

Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

View Event

Mar 18, 2026 6:00 AM EDTXOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

MilliporeSigma Marks 10 Years of SPARK™

FDA, NIH pledge flexibility and $150M for animal alternatives

2026 03 18 06 00 00 3257888

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Pari...

FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents

Click here to see all

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

View latest results

StatementsMarch 18, 2026IMC Statement on New Federal Government Task ForceOttawa, March 18, 2026 – Canada must strengthen its approach to pharmaceutical innovation in a rapidly evolving global environment. Today’s […]

Singular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-CancerMarch 18, 2026

For patients across Europe and beyond: How API manufacturing in Finland supports the availability of medicines3/18/2026 Orion Pharma and Society

Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership3/18/2026 Press release

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Investing in R&D to drive high-value pipeline delivery

Investing in manufacturing excellence at Hikma

Investing in MENA to expand access and drive growth

Investing in strategic partnerships driving growth in the US and MENA

Investing in the development of our people for long‑term growth

CVS Health Foundation invests $2.24 million to strengthen community health in Charlotte’s Historic West End

FDA Report Highlights Persistent Postmarket Burden In Implants, Commodity Quality Issues

A recent FDA report to Congress reflects ongoing safety issues with orthopedic and cardiac implants,...

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial

The drugmaker announced that its Phase II trial of atirmociclib, a CDK4 inhibitor, succeeded in pati...

FDA finalizes guidance on assessing bioequivalence of topical drugs

MDUFA VI: FDA, industry make headway in reauthorization negotiations

Recon: Judge blocks CDC’s overhaul of childhood vaccines; FDA rejects Aldeyra’s eye disorder drug

Rare Diseases Part XI: Huntington’s Disease

A 10-Year-Old Male With Four Genetic Diagnoses and a Complex Multisystem Presentation

Treatment and Management – Clinical management is complicated by multiple diagnoses. Reviewing each...

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

GSK's management of Flovent allowed it to 'game the system': Hassan

R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment

Taiwan Bio partners with Terumo to advance automated Treg manufacturing

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO, March 17, 2026 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o...

RFK Jr’s vaccine overhaul halted by federal judge’s ruling

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum b...

FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis

Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, f...

SK pharmteco Announces Successful U.S. FDA Inspection of Small Molecules Manufacturing Facility in La Porte, Texas

Flagship Pioneering Appoints Eric Topol as Academic Advisor to Advance Preemptive Health and Medicine Initiative2026

FDA rejects Aldeyra eye disease candidate for 3rd time

Alzheimer’s Association Announces New Brain Health Roundtable

BSR launches job planning guidance for pharmacists

International Women’s Day: The past, present and future of rheumatology

Generic Drug Labeling Carve-Out Scorecard

By Kurt R. Karst – With the recent litigation surrounding FDA’s approval of ANDAs for generic versio...

1FDA Approves Icotrokinra as First Targeted Oral Peptide for Moderate-to-Severe Plaque Psoriasis

Our Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability

More From Katie Anderson

Human, AI, robots: Co-creating cell therapy

Astellas & YASKAWA's joint venture, Cellafa, uses AI and a humanoid robot to revolutionize cell ther...

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the...

SmallCap Event 20th Edition

PDUFA VIII: Negotiations touch on patient experience data, reserve funding, fee waivers, and more

Intermountain Downwinders Clinic Holding Free Public Meetings in Utah to Discuss Recent Reauthorization and Expansion of Program

Experts propose new framework for overseeing genAI health tools

Asia-Pacific Roundup: India’s CDSCO posts draft legislation on manufacturing change approvals, notifications

Recon: GSK nabs FDA authorization for expanded RSV jab indication; Mideast war disrupts region’s pharma supply chain

Women Winemakers of Sonoma & Napa: Q&A with the Women Behind the Wines

March is International Women’s Month! We’re celebrating female empowerment with a fun Q&A with the w...

Five Phase III Wins On The Bounce For Bayer’s Kerendia

The mineralocorticoid receptor antagonist, which will be a key driver at the German group in the pos...

Most London patients go private to access weight loss drugs

Study finds virtual treatment can benefit eating disorder patients

Research from Oxford Health has found that virtual treatment can help prevent admissions and support...

Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis

Lebrikizumab shows strong results for children with atopic dermatitis

Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index

Research published in Dermatologic Surgery identifies inconsistencies in how patients and providers...

Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada’s Leading Medical Cannabis Business By Revenue

This news release constitutes a “designated news release” for the purposes of Canopy Growth’s prospe...

GSK’s RSV jab secures FDA label expansion to larger adult population

Widespread US shift from prescription to OTC lies in pharma’s hands

Despite boosted funding, NIH still slow to award grants: analysis

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement ( EASI -75) an...

Biophytis and LynxKite expand alliance to boost AI-driven drug discovery

Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

News16 March, 2026Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in Rheumatoid Arthritis Patients with Incomplete Response to TNFi

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluoroura...

March 16, 2026

Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide d...

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutionsMarch 16, 2026

With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s l...

Drive Clinical Trial Success with a Better Participant Payment ExperienceMar 13, 2026

Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease

Finerenone significantly delayed kidney disease progression in patients with non-diabetic chronic ki...

Idorsia announces management change

Idorsia Ltd is listed on the SIX Swiss Stock exchange, we provide an archive of our media releases o...

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara delivers significant operational efficiencies and extends cash runway through year-end 2026 A...

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Lebrikizumab delivered significant skin clearance and improved disease severity in children with moderate-to-severe atopic dermatitis

ADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful s...

20 Feb, 2026VIDEOBB Biotech 2025 Video UpdateFind out more

BB Biotech 2025 Video Update In this short video statement, Dr. Christian Koch, Head BB Biotech Team...

24 Feb, 2026EXPERT COMMENTARYFrom innovation to value realization: The biotech market in a new phaseFind out more

After several years characterized by elevated capital costs, valuation pressure and pronounced risk...

28 Jan, 2026VIDEOExecutive interview with Edison TVFind out more

Executive interview with Edison TV In this video, Dr Koch discusses the increasingly positive sentim...

13 Mar, 2026VIDEOWhy biotech is becoming attractive to investors againFind out more

Navigate to page BB Biotech AG BB Biotech AG (SIX) (CHF) ISIN-No.: CH0038389992 YTD: 2.56% Active sh...

13 Mar, 2026VIDEOBB Biotech – Active management across the biotechnology value chainFind out more

Navigate to page BB Biotech AG BB Biotech AG (SIX) (CHF) ISIN-No.: CH0038389992 YTD: 2.56% Active sh...

ქალთა დღის ფარგლებში ავერსი ფარმას თანამშრომლებისთვის გაიმართა სამოტივაციო შეხვედრა თემაზე - „სასწაული შენს ხელშია: როგორ ვმართოთ საკუთარი ცხოვრება“, რომელსაც გაუძღვა ტრენერი ლალი ბადრიძე

ქალთა დღის ფარგლებში ავერსი ფარმას თანამშრომლებისთვის გაიმართა სამოტივაციო შეხვედრა თემაზე - „სასწაუ...

FDA Weight Loss Device Guidance Calls For Patient Focus

A new final guidance document from the US FDA lays out premarket considerations for devices intended...

EMA proposes new paper on proof-of-concept studies for pediatric oncology drugs

This Week at FDA: Prasad’s second exit from FDA, ACIP backs off COVID-19 vaccine, more

Expert: Stryker cyberattack could lead FDA to reassess cybersecurity requirements

Another Late-Stage LAG-3 Trial Bites The Dust As Immutep Ends Efti NSCLC Study

The biotech stopped a Phase III trial combining Merck’s Keytruda with eftilagimod alfa in first-line...

Press releaseMar 13, 2026Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativaCosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mec...

EMA Eyes 2028 For US-Style Routine Submission Of Clinical Trial Raw Data

Prasad’s Request To Remain Anonymous Shines Light on FDA’s Transparency Problem

FDA Expands Approval for Arexvy for Adult Patients Aged 18-49

FDA And Industry To Move Forward On Commitment Letter After Agreeing On Several Proposals

During the latest round of MDUFA negotiations, the FDA and medtech industry agreed to include langua...

Parkinson’s research reaches “pivotal” stage, but barriers remain

WHO directs antibiotic development to priority pathogens

13 March 2026GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased riskIn the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection

PsiQuantum and National Cancer Center Japan partner on quantum computing

Berliner Philharmoniker und Charité: Spitzeninstitutionen vereinbaren Zusammenarbeit

บริษัท อมรินทร์ คอร์เปอเรชั่นส์ จำกัด (มหาชน) และกลุ่มบริษัทในเครือ ร่วมเป็นเจ้าภาพบำเพ็ญพระราชกุศลถวายพระบรมศพ ณ พระที่นั่งดุสิตมหาปราสาท

FDA scolds CDMO Simtra with warning letter over contamination fumbles

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMar 13, 2026

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d...

Adrienne Hoyt-Austin receives Eli Gold Prize

Pediatrician Adrienne Hoyt-Austin received the 2026 Eli Gold Prize for excellence in teaching, recog...

Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting

Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficac...

Leica Biosystems Elevates Cytogenetics with AI-Powered Karyotyping on the CytoInsight GSL Platform

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

Singapore, March 13, 2026 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Researc...

Manufacturing issues prompt FDA rejection of Hyloris antiviral

Mar 13, 2026 NewsFDA Clears Secukinumab for Adolescents With Severe Chronic Skin Disease

FDA approves secukinumab for teens 12 and older with moderate to severe hidradenitis suppurativa, of...

FDA Approves GSK's RSV Vaccine for Adults Aged 18–49 at Increased RiskMar 13, 2026

FDA expands Arexvy RSV vaccine to at-risk adults 18–49, backed by phase IIIb data—what it means for...

FDA Rejects Valacyclovir Oral Suspension NDA Over Facility cGMP FailuresMar 13, 2026

No FDA-approved oral suspension of valacyclovir currently exists, meaning pharmacies must continue r...

Feb 27, 2026Press releaseNovartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science

Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced...

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 06, 2026Press releaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Working together, we can reimagine medicine to improve and extend people’s lives.

Mar 13, 2026Press releaseNovartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Working together, we can reimagine medicine to improve and extend people’s lives.

Novartis pipeline

Working together, we can reimagine medicine to improve and extend people’s lives.

Research and development

Working together, we can reimagine medicine to improve and extend people’s lives.

Research disease areas

Working together, we can reimagine medicine to improve and extend people’s lives.

Cardiovascular and metabolic disease research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Diseases of Aging and Regenerative medicine (DARe)

Working together, we can reimagine medicine to improve and extend people’s lives.

DAx: exploratory disease research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Global Health disease area research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Immunology disease research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Neuroscience research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Oncology research at Novartis

Working together, we can reimagine medicine to improve and extend people’s lives.

Research collaborations

Working together, we can reimagine medicine to improve and extend people’s lives.

Collaborations

Working together, we can reimagine medicine to improve and extend people’s lives.

Novartis annual results

Working together, we can reimagine medicine to improve and extend people’s lives.

Novartis quarterly results

Working together, we can reimagine medicine to improve and extend people’s lives.

Share data and analysis

Working together, we can reimagine medicine to improve and extend people’s lives.

Return on investment calculator

Working together, we can reimagine medicine to improve and extend people’s lives.

Publications order form

Working together, we can reimagine medicine to improve and extend people’s lives.

Read our full statement

Working together, we can reimagine medicine to improve and extend people’s lives.

CHEK Spotlight: The Rise of Generative AI in Biopharma

Western AI Podcast: AI, Science, and the Future of Pharmaceutical Research

What’s with RWE Podcast: Generative AI for Drug Discovery

Building a Foundation Model for Drug Discovery

FDA finalizes guidance on weight-loss devices

Beyond imaging: Using molecular data to personalize cancer care

Introduction Traditional cancer surveillance relies on imaging and clinical assessments, which have...

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Euro Roundup: EMA releases strategy for implementing ICH guideline on post-approval safety data

Recon: Lilly warns of impurities in compounded versions of its weight-loss drugs; Abivax denies rumors of takeover by AstraZeneca

eXoZymes’ CCO Damien Perriman to Present a NCT solution at next week’s MISTA Symposium

Los Angeles, CA -- March 12, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of...

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (...

Vima banks $100m in Series A to progress Parkinson’s drug

Building the Future of Gene-Therapy Manufacturing with Viral Vectors

Eli Lilly finds impurity in compounded tirzepatide

MHRA approves new treatment for severe alopecia areata

Aplagon doses first patient in phase 2a trial of APAC

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors

Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

Curatis and Neupharma sign development agreement for corticorelin in Japan

WuXi Biologics and Earendil Labs Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs

Suzhou, Mar.12, 2026 – WuXi Biologics (2269.HK), a global leading Contract Research, Development and...

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatid...

The Rare Kidney Disease Labyrinth Documentary Launch

Sobi Launches New Documentary Spotlighting Life With Rare Kidney Disease Coinciding with World Kidne...

New data signals high demand in aesthetic surgery in southern, rural U.S. despite access issues

A UC Davis national analysis suggests that Southern, Midwestern and rural regions of the United Stat...

Mar 12, 2026 6:30 AM EDTXOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

FDA launches new adverse event monitoring system

Orphan Drugs at a Crossroads: Bigger Numbers, Tougher Calls

Alzheimer’s Association Looks Ahead to a New Era: Early Detection and Prevention of Cognitive Decline

Driving a patient-centered approach to hospital pharmacy

March 12, 2026ACT Brief: Trial Transparency and Synthetic Controls, Readiness as Leading Risk Indicator, FDA Streamlines Biosimilar Pathway

3/12/2026How to Get the Most out of Your Protein Language Model for Antibody Drug DesignBlog

FDA Approves Johnson & Johnson's Breakthrough Cataracts Solution

Press releaseOwkin creates new spin out Waiv, formerly Owkin Dx, with $33m financingMarch 12, 2026

Singular Genomics Names the Spatial Technologies Unit at Beth Israel Deaconess Medical Center a G4X™ Center of ExcellenceMarch 12, 2026

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, t...

News and Media Center

InflaRx to Report Full Year 2025 Results on March 19, 2026

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Ipsen appoints Michelle C. Werner as EVP, President of North America

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic Publishes Annual Report 2025

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial ResultsView Press Release02/16/2026

MENLO PARK, Calif., Feb 16, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is...

GRAIL Reports Fourth Quarter and Full Year 2025 Financial ResultsView Press Release02/19/2026

Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $1...

GRAIL to Present at the TD Cowen 46th Annual Health Care ConferenceView Press Release02/24/2026

MENLO PARK, Calif., Feb 24, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is...

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)View Press Release03/02/2026

MENLO PARK, Calif., March 2, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission i...

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as SuccessorView Press Release03/12/2026

MENLO PARK, Calif. – March 12, 2026 – GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission...

Read Release

The AMBAR ® Center in Barcelona reinforces its position as a clinical reference and training center...

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering

All News Releases

View Press Release

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, Howev...

Almirall inaugurates offices in China to advance innovation in medical dermatology through partnerships

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation...

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity

The company remains blinded to data on functional gains, holding that for future US FDA accelerated...

FDA Weighs Second Citizen Petition On Bamboo Health’s NarxCare

The FDA’s device center has received a second citizen petition relating to the NarxCare algorithm by...

Montana High School Athlete Back on Track, Thanks to Life-Saving Care at Intermountain Health St. James Hospital

EU regulators update workplan for leveraging AI and big data